AGP Executive Report
Last update: 3 hours agoClinical Trials & Pharma: Cyprumed says MSD has started a Phase I trial for an oral peptide candidate using Cyprumed’s oral delivery technology, marking its first human clinical development and triggering a milestone payment. Healthcare Supply & Patient Impact: Cyprus faces a blood shortage that could delay surgeries, with thalassemia patients warned they need transfusions every 1–2 weeks. Public Safety in Schools: Cyprus’ auditor-general warns school air-conditioner installations pose serious health and safety risks after units were reportedly installed but left unconnected, operated in rotating fashion to avoid overload, and run without required testing and approvals. Fraud Alert (GESY): Cyprus Health Insurance Organization and police issue a warning about fake GESY text messages, urging people to delete them and never click links or share personal/payment details. Local Wellness Initiative: Lidl Cyprus announces its 7th Lidl Wellness Camp (Nov 7–8, Limassol) focused on physical and mental health, balanced nutrition, longevity, mindfulness and community. Distribution Deal: TempraMed signs a non-binding LOI with CPO Cyprus for exclusive distribution of VIVI Cap™ and VIVI Epi™ across Cyprus, subject to a definitive agreement. Emergency Care & Access: A boat capsized off Dasoudi in Limassol; 21 people were rescued and checked by ambulance crews before being allowed to leave.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
